New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:04 EDTSNN, WMGI, SYK, TRNX, JNJ, IART, ZMHVolume trends from CCJR meeting positive for Zimmer, says Piper Jaffray
Piper Jaffray said it has more confidence in improving volume trends in the orthopedic market following its attendance at the Current Concepts in Joint Replacement meeting, which it views as particularly positive for Zimmer (ZMH). The firm also said the trends and expectations pointed to at the meeting were positive, but to a lesser extent, for Tornier (TRNX), Wright Medical (WMGI), Integra LifeSciences (IART), Stryker (SYK), Smith & Nephew (SNN) and Johnson & Johnson (JNJ).
News For ZMH;TRNX;WMGI;IART;SYK;SNN;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2015
06:25 EDTIARTIntegra LifeSciences sees FY15 adjusted EPS $3.00-$3.10, consensus $3.11
Sees FY15 revenue $870M-$885M, consensus $871.57M. "The new guidance range for 2015 continuing operations is consistent with our prior expectations. This new guidance reflects the removal of our spine business for the full year, which is expected to have a $0.20 dilutive impact to adjusted EPS, and the slight accretion we expect from the TEI acquisition, net of any financing impact we expect to incur in the second half of 2015," said Glenn Coleman, Integra's CFO. "We are maintaining our expectations for the underlying business excluding these transactions."
06:24 EDTIARTIntegra LifeSciences reports Q2 adjusted EPS 79c, consensus 72c
Subscribe for More Information
July 29, 2015
16:14 EDTWMGIWright Medical sees FY15 EPS ($1.67)-($1.77), consensus ($1.72)
Subscribe for More Information
16:12 EDTWMGIWright Medical reports Q2 EPS (53c), consensus (48c)
Reports Q2 revenue $80.4M, consensus $77.55M.
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
10:00 EDTIARTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 3D Systems (DDD) upgraded to Neutral from Underperform at Longbow... AK Steel (AKS) upgraded to Outperform from Neutral at Macquarie... Ally Financial (ALLY) upgraded to Outperform from Neutral at Credit Suisse... Amazon.com (AMZN) upgraded to Buy from Hold at Stifel... Arrow Electronics (ARW) upgraded to Buy from Underperform at CLSA... Beacon Roofing (BECN) upgraded to Buy from Neutral at CL King... Citrix (CTXS) upgraded to Outperform at Baird... Commvault (CVLT) upgraded to Buy from Hold at Jefferies... FireEye (FEYE) upgraded on positive checks, business mdoel changes at Oppenheimer... Hibbett Sports (HIBB) upgraded to Neutral from Underperform at Sterne Agee CRT... Integra LifeSciences (IART) upgraded to Outperform at Raymond James... M/A-COM (MTSI) upgraded to Buy from Hold at Needham... Norsk Hydro (NHYDY) upgraded to Neutral from Underperform at Exane BNP Paribas... NuVasive (NUVA) upgraded to Outperform from Market Perform at Northland... SM Energy (SM) upgraded to Outperform from Market Perform at Raymond James... Scorpio Bulkers (SALT) upgraded to Buy from Hold at Deutsche Bank... Sirius XM (SIRI) upgraded to Buy from Hold at Wunderlich... Sprouts Farmers Markets (SFM) upgraded to Neutral from Underperform at Longbow... Supervalu (SVU) upgraded to Equal Weight from Underweight at Morgan Stanley... Waters (WAT) upgraded to Outperform from Market Perform at Wells Fargo... Wells Fargo (WFC) upgraded to Buy from Neutral at Guggenheim... Williams-Sonoma (WSM) upgraded to Overweight from Neutral at JPMorgan... YRC Worldwide (YRCW) upgraded to Strong Buy at Raymond James.
07:39 EDTIARTIntegra LifeSciences upgraded to Outperform at Raymond James
Raymond James upgraded Integra LifeSciences to Outperform from Market Perform with a $73 price target. The firm said execution is improving, visibility is at a high, and the high margin product cycle coupled with capital deployment should improve sentiment and drive shares higher.
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
16:12 EDTSYKStryker sees FY15 constant currency sales growth 6.5%-7.5%, consensus $9.93B
Subscribe for More Information
16:12 EDTSYKStryker sees Q3 adjusted EPS $1.20-$1.25, consensus $1.20
Subscribe for More Information
16:10 EDTSYKStryker raises FY15 adjusted EPS view to $5.06-$5.12 from $4.95-$5.10
Subscribe for More Information
16:08 EDTSYKStryker reports Q2 adjusted EPS $1.20, consensus $1.17
Subscribe for More Information
15:04 EDTSYKNotable companies reporting after market close
Subscribe for More Information
July 22, 2015
16:22 EDTSYKSynergetics completes early renewal of Stryker supply agreement
Subscribe for More Information
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
July 20, 2015
08:04 EDTSYKStryker announces definitive agreement tyo acquire Muka Metal
Stryker announced a definitive agreement to acquire Muka Metal, A.S. in an all cash transaction. Muka, headquartered in Kayseri, Turkey, sells hospital beds, stretchers and related patient room furniture and accessories that serve markets across Turkey and other regions globally. Upon closing, the transaction is expected to be neutral to Stryker's FY15 EPS excluding acquisition, integration-related and intangible amortization charges and accretive thereafter. The transaction is expected to close in Q3.
06:04 EDTIARTSeaSpine selling pressure may be over, says at Piper Jaffray
Piper Jaffray points out that shares of SeaSpine (SPNE) are down 15% since their spin-off from Integra LifeSciences (IART) on June 17. Piper attributes the weakness to non-fundamental selling by existing Integra shareholders and its analysis indicates that the worst of the selling pressure might be over. The firm keeps an Overweight rating on SeaSpine with a $24 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use